N 6 (178) 2021. P. 28–31

HYPERPROLACTINEMIC HIPOGONADISM: TREATMENT EFFECTIVENESS PREDICTION AND MANAGEMENT

Odesa National Medical University MH of Ukraine, Odesa, Ukraine

DOI 10.54229/2226-2008-2021-6-5

Hyperprolactinemia syndrome (HPRL) is one of the most common neuroendocrine diseases, leading to the development of hypogonadism in young women. The aim of the study was to study the effectiveness of treatment of menstrual and reproductive disorders caused by hyperprolactinemia, depending on the nature of the relationship of gonadotropic hormones.

Materials and methods. 98 women of reproductive age were monitored, of which 78 — with functional HPRL and 20 healthy women. Clinical-anamnestic, enzyme-linked immunosorbent, instrumental (perimetry, computed tomography), functional, statistical research methods were used. The effectiveness of therapy for menstrual and reproductive disorders caused by HPRL, depending on the nature of the relationship of gonadotropic hormones (GH).

Results. In patients of reproductive age with HPRL there are four types of GH secretion: the first — LH and FSH levels are reduced; the second — the level of LH is increased and FSH is reduced; third — the level of LH is reduced and FSH is increased; the fourth type — LH and FSH levels are both elevated. As a result of the treatment, ovarian function was restored in the first type of GH secretion in 83.6% of patients, in the second type — in 66.7% of patients, in the third — in 37.5%. In the group of women with HPRL and high levels of GH normalization of the menstrual cycle and restoration of reproductive function did not occur.

Conclusions. Detection of four types of GH secretion in HPRL indicates the presence of different pathogenetic features of this pathology, which must be taken into account when prescribing personalized therapy to restore ovarian function and fertility, timely use of assisted reproductive technologies.

Key words: hyperprolactinemia, hypogonadism, pathogenetic features, prognosis, therapy.

REFERENCES

1. Pyrohova VI, Veresnyuk NS, Shurpyak SO. Syndrome of hyperprolactinemia in ambulatory practice of obstetrician-gynaecologist. Zdorovye zhenschiny. 2017;(9)125:10- 16.
2. Rykova OV. Hyperprolactinemia: optimal algoritm of laboratory diagnostics. Zdorovye zhenschiny. 2016;3(109):126-128.
3. Tronko MD, Antipkin YuG, Kaminskiy VV, Tatarchuk TF. et al. National consensus as for management of patients with hyperprolactinemia. Reproduktivna endokrinologiya. 2016;4 (10):8-18.
4. Paіubska S, Adamiak-Godlewska A, Winkler I, Romanek-Piva K, Rechberger T, Gogacz M. Hyperprolactinaemia — a problem in patients from the reproductive period to the menopause. Prz Menopauzalny. 2017;16:1-7. DOI: 10.5114/pm.2017.67364.
5. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM. et al. Diagnosis and treatment of hypeprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011;96(2):273-88.
6. Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015 Jul;31(7):506-10. DOI: 10.3109/09513590.2015.1017810. Epub 2015 Jul 6.
7. Matalliotakis M, Koliarakis I, Matalliotaki C, Trivli A, Hatzidaki E. Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review. Acta Biomed. 2019;90(1):149-157. DOI: 10.23750/abm.v90i1.8142.
8. Vilar L, Vilar CF, Lyra R, Freitas MDC. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019;109(1):7-19. DOI: 10.1159/000499694. Epub 2019 Mar 20. PMID: 30889571
9. Macotela Y., Triebel J., Clapp C. Time for a New Perspective on Prolactin in Metabolism. Trends Endocrinol Metab. 2020;31(4):276-286. https://doi.org/10.1016/j.tem.2020.01.004
10. Pereira-Lima JFS, Leгes CGS, Neto FMF, Barbosa MV, Silva ALM, Oliveira M. Hyperprolactinemia and body weight: prevalence of obesity and overweight in patients with hyperprolactinemia. Res J Endocrinol Metab. 2013;1(1):2. https://doi.org/10.7243/2053-3640-1-2.
11. Melnichenko GA, Dzeranova LK, Pigarova EA. National questionary about management of hyperprolactinemia under real clinical practice. Ozhirenie i metabolizm. 2016;13 (2):14-19.
12. Salvatori R. Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine. 2018;59 (1):4-6. DOI: 10.1007/s12020-017-1469-0
13. Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine. 2018;59(1):50-61. DOI: 10.1007/s12020-017-1444-9
14. Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernandez-Balsells MM, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012 Jul 24;1:33. DOI: 10.1186/2046-4053-1-33.